Home

United States Chinese Anti-Cancer Association, is organized under the "general Not for Profit Corporation
Act" of the State of California, United States, exclusively for educational, scientific and charitable purposes.

The mission of the association is:

1、Facilitates collaborations among Chinese American professionals in the field of cancer research, treatment and prevention;

2、Promotes knowledge and information exchange between the professionals in the United States and China;

3、Provides educational information to serve cancer patients, their families, and the community.

The Latest News

Congratulations to the newly elected President Shi-Yuan Cheng at the ACACR Inaugural Meeting, April 2, 2017, Washington DC

Shiyuan Cheng, Professor at Feinberg School of Medicine of Northwestern University was elected as the new President of the newly formed Association for Chinese Americans in Cancer Research (ACACR) at the Inaugural Meeting, April 2, 2017 (also a joint meeting of USCACA and ACACR) at the 2017 AACR Annual meeting in Washington DC. Shi-Yuan was also the past President of USCACA (2013-2016), and his outstanding service for USCACA was recognized by an outstanding service plate presented by his successor, Qingyi Wei, the new President of USCACA.

USCACA Welcomes Its New President - Qingyi Wei


Qingyi Wei, Professor at Duke University School of Medicine and Associate Director of Duke Cancer Institute, Duke University Medical Center, was elected to be the new president of USCACA at the joint meeting of USCACA and ACACR at the 2017 AACR Annual meeting in Washington DC.


中国原创三代EGFR-TKI,期待中的下一个“明星”


在刚刚闭幕的IASLC WCLC 2016上,靶向药物无疑再次捍卫了其在晚期非小细胞肺癌(NSCLC)治疗领域的“明星”地位。新型靶点的探索,传统药物新治疗领域的拓展,液体检测在靶向药物疗效预测中的价值等研究,纷纷登录主席专场、口头报告、壁报等各种展示环节。

12月7日,在“靶向治疗新策略”口头报告环节发布的一项“突变选择性EGFR抑制剂AC0010(艾维替尼)在EGRF T790M非小细胞肺癌患者中的I、II期研究”,因其使用中国首个原创三代EGFR-TKI药物而备受关注。



Sponsor and Partner